English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Bong-Soo Cha DOI: 10.3252/pso.eu.17ece.2015 Obesity and cardiovascular endocrinology Cilostazol, a selective inhibitor of phosphodiesterase 3 (PDE3), which has been widely used in patients with atherosclerotic diseases, is known to have additional beneficial effects on dyslipidemia. However, the mechanism whereby cilostazol increases plasma high-density-cholesterol(HDL) is not completely understood. ATP-binding cassette transporter A1(ABCA1), a membrane protein, which mediates the transport of cellular cholesterol and phospholipid to lipiddeficient apolipoproteins, is known to play a critical role in the regulation of intracellular cholesterol levels in hepatocytes.

endocrine abstracts

Increased expression of ATP-binding cassette transporter A1 by cilostazol may be a possible mechanism for its protective effect against hepatic steatosis